UroGen Pharma Ltd.
DE ˙ DB ˙ IL0011407140
23,18 € ↑0,82 (3,67%)
2026-06-05
CENA AKCJI
SecurityDE:UR8 / UroGen Pharma Ltd.
InstitutionInvesco Ltd.
Latest Disclosed Ownership28,080 shares
Latest Disclosed Value $ 504,878
Invesco Ltd. reports 3.75% increase in ownership of UR8 / UroGen Pharma Ltd.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 28,080 shares of UroGen Pharma Ltd. (DE:UR8) valued at $409,968 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 27,066 shares of UroGen Pharma Ltd.. This represents a change in shares of 3.75% during the quarter. The current value of the position is $650,894 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F UROGEN PHARMA COM M96088105 28,080 1,014 3.75 505 -20.38 0.0001
2026-02-19 2025-12-31 13F UROGEN PHARMA COM M96088105 27,066 4,711 21.07 634 42.25 0.0001
2025-11-13 2025-09-30 13F UROGEN PHARMA COM M96088105 22,355 9,614 75.46 446 155.75 0.0001
2025-08-13 2025-06-30 13F UROGEN PHARMA COM M96088105 12,741 31 0.24 175 24.29 0.0000
2025-05-12 2025-03-31 13F UROGEN PHARMA COM M96088105 12,710 -746 -5.54 141 -2.10 0.0000
2025-02-13 2024-12-31 13F UROGEN PHARMA COM M96088105 13,456 634 4.94 143 -11.73 0.0000
2024-11-12 2024-09-30 13F UROGEN PHARMA COM M96088105 12,822 1,159 9.94 163 -16.92 0.0000
2024-08-13 2024-06-30 13F UROGEN PHARMA COM M96088105 11,663 905 8.41 196 21.12 0.0000
2024-05-14 2024-03-31 13F UROGEN PHARMA COM M96088105 10,758 656 6.49 161 6.62 0.0000
2024-02-13 2023-12-31 13F UROGEN PHARMA COM M96088105 10,102 47 0.47 152 7.86 0.0000
2023-11-13 2023-09-30 13F UROGEN PHARMA COM M96088105 10,055 10,055 141 0.0000
2019-05-15 2019-03-31 13F UROGEN PHARMA COM M96088105 0 -6,078 -100.00 0 -100.00
2019-02-14 2018-12-31 13F UROGEN PHARMA COM M96088105 6,078 6,078 262 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.